content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Bluebird Bio (BLUE)

126.90
2.10
(1.68%)
Sep 11, 4:00PM EDT
content_middle

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company’s product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Previous Close: 
124.80
Open: 
125.55
Bid: 
126.65
Ask: 
127.00
1yr Target Price: 
116.47
Day's Range: 
124.80 - 128.30
52wk Range: 
37.05 - 133.10
Volume: 
729138
Average Daily Volume: 
966749
Market Capitalization: 
5.79B
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
45589000M
content_right

Pages